Global Live Cell Encapsulation Market Size To Worth USD 318.06 Million By 2033 l CAGR Of 3.52%
03. Juli 2024 22:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States, July 03, 2024 (GLOBE NEWSWIRE) -- The Global Live Cell Encapsulation Market Size is to Grow from USD 225.10 Million in 2023 to USD 318.06 Million by 2033, at a Compound...
Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market
07. Juli 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jul 7, 2014) - Nuvilex, Inc. (OTCQB: NVLX) announced last week that its executives recently met with the company's "global development partners" at the 2014 BIO...
Nuvilex's Acquisition of Diabetes Rights Should Put the Company on Everyone's Radar
19. November 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Nov 19, 2013) - Nuvilex, Inc. (OTCQB: NVLX) recently acquired the exclusive worldwide rights to a proprietary cellulose-based live-cell encapsulation technology for...
Investors Confidently Back Nuvilex's Acquisition of Diabetes Technology
12. November 2013 08:45 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Nov 12, 2013) - Nuvilex, Inc. (OTCQB: NVLX) announced last week that it has acquired the exclusive worldwide rights to a cellulose-based live-cell encapsulation...
Nuvilex Announces Cloning of Cells for Future Phase 3 Clinical Trials Initiated by Inno Biologics
04. November 2013 09:56 ET
|
Nuvilex, Inc.
SILVER SPRING, MD--(Marketwired - Nov 4, 2013) - Nuvilex, Inc. (OTCQB: NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases,...
Is Nuvilex Ready to Acquire Diabetes Technology and Control Cancer and Diabetes Cell Encapsulation Markets?
01. November 2013 09:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Nov 1, 2013) - With October behind us, Nuvilex, Inc. (OTCQB: NVLX) investors should see a new acquisition this month. Two weeks ago Stock Market Media Group, a...
Nuvilex, Inc.'s COO, Dr. Gerald Crabtree, Interviews With Stock Market Media Group
17. Oktober 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Oct 17, 2013) - Nuvilex Inc.'s, (OTCQB: NVLX) Chief Operating Officer, Dr. Gerald Crabtree sat down for an interview with Stock Market Media Group, a research and...
Nuvilex, Inc. Enters Most Important Step of Phase III Trials Outside of Patient Enrollment
01. Oktober 2013 08:45 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Oct 1, 2013) - When Nuvilex, Inc. (OTCQB: NVLX) announced that it had contracted Inno Biologics to generate cell clones that will be the basis of the company's future...
Nuvilex, Inc. Names Two Significant Partners on Its Way to Phase 3 Clinical Trials
19. September 2013 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Sep 19, 2013) - Nuvilex, Inc. (OTCQB: NVLX) made another subtle but significant move this week that seems to signal the company is in "go-mode" on its future Phase III...
Nuvilex Remains Under Fire While Investors Hold
27. August 2013 10:10 ET
|
Nuvilex, Inc.
SAN DIEGO, CA--(Marketwired - Aug 27, 2013) - The OTC Journal, the longest running electronic newsletter focused on the small cap and microcap sectors, suggests investors consider the agenda when...